Question

Manuela Perteghella

Liberal Democrat — Stratford-on-Avon

To ask the Secretary of State for Health and Social Care, whether her Department has made an assessment of the potential merits of making trastuzumab deruxtecan (Enhertu) available on the NHS to patients with strongly HER2-positive rare cancers, including